The Radiation Oncology Journal (ROJ) is a peer-reviewed publication of the Korean Society for Radiation Oncology. The ROJ is published quarterly on the last day of March, June, September, and December, one volume per year. Any physicians or researchers throughout the world can submit a manuscript if the scope of the manuscript is appropriate. Articles in the following categories will be published: original articles, invited review articles, case reports, editorials, and letters to the Editor related to basic or clinical radiation oncology.
Manuscripts for submission to ROJ should be prepared according to the following instructions. ROJ follows the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (http://www.icmje.org/urm_main.html) commonly known as "the Vancouver style," if not otherwise described below.
1. RESEARCH AND PUBLICATION ETHICS
For the policies on the research and publication ethics not stated in this site, Good Publication Practice Guidelines for Medical Journals or Guidelines on Good Publication can be applied..
(1) Journal policies on authorship and contributorship
1) Authorship Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreeing to be accountable for all aspects of the work in ensuring that the questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet these 4 conditions. 2) Originality and Duplicate Publication All submitted manuscripts should be original and should not be considered by other scientific journals for publication at the same time. Any part of the accepted manuscript should not be duplicated in any other scientific journal without the permission of the editorial board. If duplicate publication related to the papers of this journal is detected, the authors will be announced in the journal and their institutes will be informed, and there will also be penalties for the authors. 3) Secondary Publication It is possible to republish manuscripts if the manuscripts satisfy the conditions of secondary publication of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. ROJ maintains a zero-tolerance policy when addressing allegations of plagiarism, duplicate publication (self-publication), data falsification, and scientific misconduct. Articles will be retracted if ethics violations are substantiated. Plagiarism is defined by the World Association for Medical Editors (WAME) as the "use of others' published and unpublished ideas or words (or other intellectual property) without attribution or permission, and presenting them as new and original rather than derived from an existing source." ROJ participates in the CrossCheck/iThenticate program to investigate incidents of possible plagiarism. Manipulating data through fabrication, omission, or intentional distortion is unacceptable. Authors should be prepared to provide original data to editors if there is a question of authenticity. Claims of scientific misconduct are investigated and addressed, guided by the Committee of Publication Ethics (COPE) Code of Conduct.
(2) Statement of Informed Consent
Copies of written informed consent and Institutional Review Board (IRB) approval for clinical research should be kept. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval and study conduct.
(3) Statement of Human and Animal Rights
All human investigations must be conducted according to the principles expressed in the Declaration of Helsinki. All studies involving animals must state that the guidelines for the use and care of laboratory animals of the authors’ institution, or any national law, were followed.
(4) How the journal will handle complaints and appeals
When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The Editorial Board of ROJ will discuss the suspected cases and reach a decision. ROJ will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed
(5) Journal policies on conflicts of interest/competing interests
Conflict of interest exists when an author or the author’s institution, reviewer, or editor has financial or personal relationships that inappropriately influence or bias his or her actions. Such relationships are also known as dual commitments, competing interests, or competing loyalties. These relationships vary from being negligible to having great a potential for influencing judgment. Not all relationships represent true conflict of interest. On the other hand, the potential for conflict of interest can exist regardless of whether an individual believes that the relationship affects his or her scientific judgment. Financial relationships such as employment, consultancies, stock ownership, honoraria, and paid expert testimony are the most easily identifiable conflicts of interest and the most likely to undermine the credibility of the journal, the authors, or of the science itself. Conflicts can occur for other reasons as well, such as personal relationships, academic competition, and intellectual passion (http://www.icmje.org/conflicts-of-interest/). If there are any conflicts of interest, authors should disclose them in the manuscript. The conflicts of interest may occur during the research process as well; however, it is important to provide disclosure. If there is a disclosure, editors, reviewers, and reader can approach the manuscript after understanding the situation and background for the completed research. The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data.
(6) Journal policies on data sharing and reproducibility
1) Open data policy For clarification on result accuracy and reproducibility of the results, raw data or analysis data will be deposited to a public repository after acceptance of the manuscript. Therefore, submission of the raw data or analysis data is mandatory. If the data is already a public one, its URL site or sources should be disclosed. If data cannot be publicized, it can be negotiated with the editor. If there are any inquiries on depositing data or waiver of data sharing, authors should contact the editorial office. 2) Clinical data sharing policy This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018 manuscripts submitted to ICMJE journals that report the results of interventional clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained at https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record. All of the authors of research articles that deal with interventional clinical trials must submit data sharing plan. Based on the degree of sharing plan, authors should deposit their data after deidentification and report the DOI of the data and the registered site.
(7) Journal's policy on ethical oversight
When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The Editorial Board will discuss the suspected cases and reach a decision. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.
(8) Journal's policy on intellectual property
All published papers become the permanent property of the Korean Society for Radiation Oncology. Copyrights of all published materials are owned by the Korean Society for Radiation Oncology.
(9) Journal's options for post-publication discussions and corrections
The post-publication discussion is available through letter to editor. If any readers have a concern on any articles published, they can submit letter to editor on the articles. If there founds any errors or mistakes in the article, it can be corrected through errata, corrigenda, or retraction.
2. ELECTRONIC SUBMISSION OF MANUSCRIPT
Manuscript submission is only available through the online submission site at http://submit.e-roj.org. Submission instructions are available at the website. All articles submitted to the ROJ must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication. For assistance please contact us via E-mail (email@example.com), telephone (+82-2-3410-2612).
3. PEER REVIEW PROCESS
The acceptance criteria for all papers are based on the quality and originality of the research and its clinical and scientific significance. Original Articles are generally reviewed at least by two peer reviewers. The Editor-in-Chief is responsible for final decisions regarding the acceptance if a peer-reviewed paper. An initial decision will normally be made within 4 weeks of receipt of a manuscript, and the reviewers’ comments are sent to the corresponding authors by E-mail. Revised manuscripts must be submitted online by the corresponding author. The corresponding author must indicate the alterations that have been made in response to the referees’ comments item by item. Failure to resubmit the revised manuscript within 12 weeks of the editorial decision is regarded as a withdrawal.
4. MANUSCRIPT PREPARATION
(1) General Guideline
Authors are required to submit their manuscripts after reading the following instructions. Any manuscript that does not conform to the following requirements will be considered inappropriate and may be returned. When a manuscript is received for consideration, the editors assume that no similar paper has been or will be submitted for publication elsewhere. The main document with manuscript text and tables should be prepared with an MS-word programs.
Manuscripts must be written succinctly in clear, grammatical English. All manuscripts originating from non-English speaking countries must be revised by a professional linguistic reviewer. Medical terminology should be written based on the most recent edition of Dorland’s Illustrated Medical Dictionary or the most recent edition of English-Korean Korean-English Medical Terminology, published by the Korean Medical Association. The use of acronyms and abbreviations is discouraged and should be kept to a minimum. When used, they are to be defined where first used, followed by the acronym or abbreviation in parentheses. Drug and chemical names should be stated in standard chemical or generic nomenclature. Units of measure should be presented according to the SI units (e.g., Gy, Sv, Bq, m, kg, L).
(3) Reporting Guidelines for Specific Study Designs
For the specific study design, such as randomized control studies, studies of diagnostic accuracy, meta-analyses, observational studies and non-randomized studies, it is recommended that the authors follow the reporting guidelines listed in the following table.
Original articles are reports of basic or clinical investigations. The manuscript for an original article should be organized on a separate page in the following sequence: title page, abstract and keywords, text (introduction, materials and methods, results, discussion and conclusion), conflicts of interest, acknowledgments (if necessary), references, tables, and figure legends.
1) Title page
Title Page should carry the following information.
2) Abstract and Keywords
The abstract should be no more than 250 words, and describe concisely, in a paragraph, Purpose, Materials and Methods, Results, and Conclusion. Up to six keywords should be listed below the abstract. For selecting keywords, refer to the Medical Subject Headings; if suitable MeSH terms are not yet available for recently introduced terms, present terms may be used.
Text should be arranged in following order: Introduction, Materials and Methods, Results, Discussion and Conclusion. Materials and Methods section should include sufficient details of the research design, subjects, and methods. Sufficient details need to be addressed in the methodology section of an experimental study so that it can be further replicated by others. The sources of special chemicals or reagents should be given along with the source location (name of the company, city, state/province, and country). If needed, information on the institutional review board/ethics committee approval or waiver and informed consent are included. Methods of statistical analysis and criteria for statistical significance should be described.
4) Conflicts of Interest
All potential conflicts of interest must be stated within the text of the manuscript, under this heading. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the article. Such relationships include, but are not limited to, employment by an industrial concern, ownership of stock, membership on a standing advisory council or committee, being on the board of directors, or being publicly associated with the company or its products. Other areas of real or perceived conflict of interest could include receiving honoraria or consulting fees or receiving grants or funds from such corporations or individuals representing such corporations. Please state "None" if no conflicts exist.
If necessary, persons who have made substantial contributions, but who have not met the criteria for authorship, are acknowledged here. All sources of funding applicable to the study should be stated here explicitly.
In the text, references should be cited with Arabic numerals in brackets, numbered in the order cited. In the references section, the references should be numbered in order of appearance in the text and listed in English. List all authors if there are less than or equal to six authors. List the first three authors followed by “et al.” if there are more than three authors. If an article has been published online, but has not yet been given an issue or pages, the digital object identifier (DOI) should be supplied. Journal titles should be abbreviated in the style used in Medline. Other types of references not described below should follow Citing Medicine: The NLM Style Guide for Authors, Editors, and Publishers.
Journal articles:7) Tables
1. Yu JI, Park HC, Choi DH, et al. Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. Radiat Oncol J 2016;34:34-44.
2. Childs SK, Kozak KR, Friedmann AM, et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys. 2011 Mar 4 [Epub]. http://dx.doi.org/10.1016/j.ijrobp.2010.11.048.
3. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG. Abeloff's clinical oncology. 4th ed. Philadelphia, PA: Churchill Livingstone; 2008.
4. Jain RK, Kozak KR. Molecular pathophysiology of tumors. In: Halperin EC, Perez CA, Brady LW, editors. Perez and Brady's principles and practice of radiation oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. p. 126-41.
5. Medin PM, Foster RD, von der Kogel, Sayre J, Solberg TD. Spinal cord tolerance to reirradiation with radiosurgery: a swine model. In: 52th ASTRO Annual Meeting; 2010 Oct 31 - Nov 11; San Diego, CA, USA. Farifax, VA: ASTRO; 2010.
6. American Cancer Society. Cancer facts & figures [Internet]. Atlanta, GA: American Cancer Society; c2011 [cited 2011 Feb 20]. Available from: http://www.cancer.org/Research/CancerFactsFigures/index.
7. National Cancer Information Center. Cancer incidence [Internet]. Goyang (KR): National Cancer Information Center; c2011 [cited 2011 Oct 20]. Available from: http://www.cancer.go.kr/cms/statics.
Each table should be typed in the separate sheet. The title of the table should be on top placed and the first letter of all word (except articles, conjunctions, prepositions) should be capitalized. Tables are numbered in order of citation in the text. Lower case letters in superscripts a), b), c) ... should be used for special remarks. Within a table, if a non-standard abbreviation is used or description may be necessary, then list them under annotation below. The statistical significance of observed differences in the data should be indicated by the appropriate statistical analysis.
Upload each figure as a separate image file. The figure images should be provided in PowerPoint file, TIFF, JPEG, GIF or EPS format with high resolution (preferably 300 dpi for figures and 600 dpi for line art and graph). The figures should be sized to column width (8.5 cm or 17.5 cm). If figures are not original, author must contact each publisher to request permission and this should be remarked on the footnote the figure. Figures should be numbered, using Arabic numerals, in the order in which they are cited. All figures should be cited in the text (e.g., Fig. 1, Fig. 1A-C, Figs. 1 and 2). In the case of multiple prints bearing the same number, use capital letters after the numerals to indicate the correct order (e.g., Fig. 1A, Fig. 1B). A figure legend should be in English and a one-sentence description rather than a phrase or a paragraph. Capitalize the first letter of the first word. A legend for each light microscopic photograph should include name of stain and magnification. Electron microscopic photograph should have an internal scale marker.
Reviews should be comprehensive analyses of specific topics. They are organized as follows: title page, abstract and keywords, introduction, body text, conclusion, conflicts of interest, acknowledgments (if necessary), references, tables, and figure legends. Upload each figure as a separate image file. There should be an unstructured abstract equal to or less than 200 words. References should be obviously related to documents and should not exceed 50.
Case reports will be published only in exceptional circumstances, when they illustrate a rare occurrence of clinical importance. The manuscript for a case report should be organized in the following sequence: title page, abstract and keywords, introduction, case report(s), discussion, conflicts of interest, acknowledgments (if necessary), references, tables, and figure legends. Upload each figure as a separate image file. The abstract should be unstructured and its length should not exceed 150 words. References should be obviously related to documents and should not exceed 20. It is not necessary to use the word “introduction.”
Editorials should be commentaries on articles published recently in the journal. Editorial topics could include active areas of research, fresh insights, and debates. Editorials should be no more than four to five pages in length including references, tables, and figures.
LETTERS TO THE EDITOR
Letters to the Editor should include brief constructive comments that concern previously published papers. Letters to the Editor should be no more two pages. It should have maximum 5 references, 1 table and 1 figure. Letters could be edited by the Editorial Board. Responses by the author of the subject paper may be provided in the same issue or next issue of the Journal
5. COMMUNICATIONS TO THE PUBLISHER
We invite inquiries to the editorial office at any time during the editorial process. For all matters concerning presubmission, editorial policies, procedures, business inquiries, subscription information, orders, or changes of address, please contact editorial office.
Editorial Committee Office
The Korean Society for Radiation Oncology
Department of Radiation Oncology, Samsung Medical Center,
81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
E-mail: firstname.lastname@example.org, homepage: http://e-roj.org
6. ADDITIONAL INFORMATION
All published papers become the permanent property of The Korean Society for Radiation Oncology. Upon acceptance of the manuscript, the authors will be required to sign a statement confirming that the manuscript contains no material the publication of which violates any copyright or other personal or proprietary right of any person or entity.
(2) Page Proofs
Corresponding authors are provided with page proofs and are asked to carefully review them for data and typesetting errors. When proofs are available, the corresponding author will receive a notification. Corrections to proofs must be returned via e-mail within 48 hours. Publication may be delayed if proofs are not returned by the publisher’s deadline.
There are no charges for submission and publication.
NOTICE: These recently revised instructions for authors will be applied beginning with the June 2016 issue.